Ampath CHAT edition 44, published in June 2017, reviews vitamin D sources, metabolism, deficiency, screening and treatment. It announces revised reporting thresholds aligned with Institute of Medicine recommendations and the 2017 NOFSA guidelines: deficiency below 12 ng/ml, insufficiency at 12 - 19 ng/ml and sufficiency at 20 ng/ml or above. The document also discusses dietary intake, clinical and biochemical findings, high-risk groups, supplementation, monitoring and safety considerations.
Free preview text
The first 4 pages, shown as text so search engines and readers can find this document.
Page 1
Dr Marita du Plessis
Please contact your local Ampath pathologist for more information.
CHAT
After much consideration about the most appropriate cutoffs to define adequate vitamin D status,
Ampath has decided to lower the currently reported cutoffs to those proposed by the Institute of
Medicine, and recently endorsed by the National Osteoporosis Foundation of South Africa. According to
these guidelines, a 25-hydroxyvitamin D level < 12 ng/ml is regarded as vitamin D deficient, with levels
between 12 and 19 regarded as insufficient and levels of 20 ng/ml or above as sufficient.
Vitamin D overview
Edition no. 44June 2017
Overt vitamin D deficiency manifesting as osteomalacia
or rickets is now uncommon in developed countries.
However, the incidence of subclinical vitamin D deficiency
presenting with low bone mass on bone densitometry,
muscle weakness and risk of falls and fragility fractures may
be higher than expected, especially in the elderly where
both vitamin D stores and the skin’s ability to convert
7-dehydrocholesterol to vitamin D decline with age.
The prevalence of vitamin D deficiency is dependent on
the vitamin D level used to define deficiency. The National
Health and Nutrition Survey (NHANES) 2005–2006 has shown
that 41.6% of all adults in the United States (aged 20 years
and older) have vitamin D levels below 20 ng/ml.1, 2
Data for South Africa is limited, with a previous retro-
spective analysis of laboratory results at Tygerberg Hospital
showing a prevalence of 41% for vitamin D results below
15 ng/ml. A more recent study done at the National
Health Laboratory Service (NHLS) in Johannesburg in
adult patients (aged 18 to 65 years) confirmed expected
seasonal, ethnic and sexual differences. The prevalence
of vitamin D levels below 12 ng/ml was 28.6% in Indians
compared to just over 5% in black Africans. Other ethnic
groups were not studied.3
Although there is some evidence to support the benefit of
vitamin D on extraskeletal health, including the immune
and cardiovascular systems, most recommendations are
based on the beneficial effect of vitamin D on skeletal
health, for which consistent and conclusive evidence of
benefit exists.1, 2, 5
Sources of vitamin D
UVB sunlight exposure is the main source of vitamin D and
is influenced by season, latitude, indoor working hours, skin
pigmentation, clothing style and use of sunscreen. There
is large interindividual variation in the vitamin D synthetic
ability of the skin. Only a small part of vitamin D comes
from dietary sources, mainly fatty fish, and supplemented
food products (such as milk, infant formula and breakfast
cereal), but this becomes more important when sun
exposure is restricted, e.g. in the aged, infants and
disabled persons.
Figure 1: Vitamin D synthesis, metabolism and effects on
calcium and phosphate homeostatis
Page 2
Edition no. 44
Please contact your local Ampath pathologist for more information.
Vitamin D synthesis and metabolism
Previtamin D3 is synthesized nonenzymatically in the skin
from 7-dehydrocholesterol during ultraviolet exposure. It
then undergoes a temperature-dependent rearrangement
to form vitamin D3 (cholecalciferol). Vitamin D from the
diet or dermal synthesis is biologically inactive and requires
enzymatic conversion in the liver (25-hydroxylation) and
kidney (1-alpha-hydroxylation) to the active metabolite
1,25-dihydroxyvitamin D (calcitriol). Renal alpha-1-
hydroxylase enzyme activity is primarily stimulated by
an increase in parathyroid hormone (PTH) secondary
to hypocalcaemia, as well as by hypophosphataemia.
Fibroblast growth factor 23 (FGF23) inhibits renal production
of 1,25-dihydroxyvitamin D. The 1,25-dihydroxyvitamin D
production in turn inhibits PTH synthesis and secretion,
and stimulates FGF23 production, creating a negative
feedback loop.
Both 1,25-dihydroxyvitamin D and 25-hydroxyvitamin D
[25(OH)D] are degraded in part by 24-hydroxylation. The
liver also has the capacity to metabolise 25(OH)D to other
inactive metabolites.1
The 1-alpha-hydroxylase enzyme is also expressed in
extrarenal sites, which becomes of clinical relevance in
granulomatous disorders (such as sarcoidosis, tuberculosis
and chronic fungal infections) and some lymphomas where
unregulated 1,25-dihydroxyvitamin D production occurs in
activated macrophages, resulting in hypercalcaemia and
hypercalciuria.
Definition of normal vitamin D status
The recommended test for the assessment of vitamin D
status is serum total 25-OH vitamin D [25(OH)D] levels as it is
believed to reflect both the vitamin D from dietary sources
as well as dermal synthesis. There is, however, controversy
about the optimal level.
Some authors advocate levels of 20–40 ng/ml, while others,
including the National Osteoporosis Foundation (NOF) and
the American Geriatric Society (AGS), favour maintaining
levels between 30 and 50 ng/ml, especially in older adults
to minimise the risk of falling and fractures.2 The Endocrine
Society Clinical Practice Guidelines, published in 2011,
define vitamin D deficiency as a level below 20 ng/ml, with
an intermediary zone of vitamin D insufficiency from
20–29 ng/ml,4 and these guidelines have been used by
Ampath for reporting since 2014.
The most recent Revised South African Clinical Guidelines
for the Diagnosis and Treatment of Osteoporosis published
by the National Osteoporosis Foundation of South Africa
(NOFSA) in 2017, however, supports the Institute of
Medicine (IOM) 2010 guidelines5 that define vitamin D
deficiency as a level below 12 ng/ml (30 nmol/l), vitamin
D insufficiency as a level of 12–19 ng/ml and vitamin D
sufficiency as a level of 20 ng/ml (50 nmol/l) and above.6
A vitamin D level of 20 ng/ml or above is regarded by the
IOM as the level at which 97.5% of the population would
achieve an adequate bone health benefit.5 Ampath will,
in future, be using these cutoffs for reporting.
Although several epidemiological studies suggest that a
25(OH)D level above 30 ng/ml may have additional health
benefits in reducing risk of common cancers, autoimmune
diseases, type 2 diabetes, cardiovascular disease
and infectious diseases, these claims have not been
substantiated in randomised clinical trials.4, 5
There is also debate regarding the safe upper limit. An
upper limit of 100 ng/ml has previously been advocated.4, 7
However, recent guidelines point towards a level of
50–60 ng/ml, due to concerns of adverse outcomes related
to all cause mortality, chronic diseases, falls and fractures
at higher vitamin D levels.5 Evidence also exists regarding
a potentially increased risk for some cancers (including
pancreatic and prostate cancer) with levels above 30 ng/
ml to 48 ng/ml.2, 5 Studies performed with high sun exposure
in young adults have shown an apparent physiological
ceiling at 60ng/ml.8 Prolonged exposure of the skin to
sunlight does not produce toxic amounts of vitamin D3 due
to photoconversion of previtamin D to inactive metabolites,
and induction of melanin production.1 Although vitamin D
intoxication has previously been defined as a 25(OH)
vitamin D level above 150 ng/ml,7 hypercalcaemia and
hypercalciuria have been described with levels above
88 ng/ml.2
Optimal vitamin D intake to prevent deficiency (assuming
minimal sun exposure and adequate calcium intake to
obtain beneficial effects on skeletal health)4, 5, 6
• The recommended dietary allowance (RDA) for adults
aged 19–70 years is 600 IU/d of vitamin D (daily calcium
requirement: 1 000 mg 19–50 years old and males 51–70
years, 1 200 mg for females 51–70 years).
• Older persons (>70 years) confined indoors and other
high-risk groups may have higher requirements:
- The NOF and AGS recommend a daily
vitamin D intake of 800 and 1 000 IU/d respectively
in older persons to reduce the risk of fractures
and falls (daily calcium requirement: 1 200 mg for
>70 years old).
Page 3
Please contact your local Ampath pathologist for more information.
Edition no. 44
- Pregnant and lactating women require at least
600 IU/d, although 1 500 to 2 000 IU/d may be
needed to maintain adequate levels (daily
calcium requirement: 1 000 to 1 300 mg).
- Obese patients, those with malabsorption
syndromes or on medications affecting vitamin D
metabolism (including long-term glucocorticoids,
anticonvulsants, antifungals such as ketoconazole
and antiretroviral treatment), require a 2 to 3 times
higher dose for their age group.
• The maintenance tolerable upper limit of vitamin D,
which is not to be exceeded without medical
supervision, is 4 000 IU/d for healthy adults.1, 4, 5 The
applicable level for calcium is 2 500 mg/day for adults
aged 19 to 50 years, and 2 000 mg/day for those older
than 50 years.5, 6
Causes of vitamin D deficiency or resistance
• Decreased availability of vitamin D due to inadequate
dietary intake, fat malabsorption disorders and/or lack
of sunlight.
• Decreased endogenous synthesis via decreased
25-hydroxylation by the liver (liver failure) or decreased
1,25-hydroxylation by the kidneys (vitamin D-dependent
rickets type 1, chronic renal insufficiency).
• Increased hepatic catabolism due to drugs
inducing P450-enzyme activity, including phenytoin,
phenobarbital, carbamazepine, oxcarbazepine,
isoniazid, theophyllin and rifampicin.
• Increased renal loss of vitamin D-binding protein
(e.g. nephrotic syndrome).
• End organ insensitivity to vitamin D metabolites
(hereditary vitamin D-resistant rickets/HVDRR, vitamin D-
dependent rickets type 2).
Clinical manifestations and biochemistry of vitamin D
deficiency
Clinical manifestations depend on the duration and severity
of vitamin D deficiency. The majority of patients with
moderate to mild vitamin D deficiency are asymptomatic
and have normal serum calcium, phosphorus and alkaline
phosphatase (ALP) levels.
With prolonged severe vitamin D deficiency [25(OH)D levels
5–8 ng/ml], intestinal absorption of calcium and phosphorus
is decreased, and during early stages, hypophosphataemia
is more pronounced than hypocalcaemia. As vitamin D
deficiency persists, hypocalcaemia will occur, leading
to secondary hyperparathyroidism, which causes
phosphaturia, demineralisation of bones and eventually
osteomalacia in adults, and rickets and osteomalacia in
children.1, 2, 6
Additional laboratory testing to consider with vitamin D
deficiency includes serum calcium, phosphorus, ALP, PTH,
electrolytes, urea and creatinine.2
Determination of 1,25-dihydroxyvitamin D is reserved for
the monitoring of specific conditions, such as acquired or
inherited diseases of vitamin D and phosphate metabolism.
High-risk groups for vitamin D deficiency requiring screening
Most experts agree that widespread screening for vitamin D
deficiency is unnecessary, but that screening should be
aimed at the following high-risk groups:4
• Older adults, in particular the frail institutionalised elderly
• Limited effective sun exposure due to dark skin, clothing,
consistent use of sunscreens, being institutionalised/
hospitalised
• Obesity (fat tissue serves as a reservoir for vitamin D3 and
usually less sun exposure)
• Osteoporosis
• Medication accelerating vitamin D metabolism, e.g.
phenytoin
• Malabsorptive diseases, including inflammatory bowel
disease and celiac disease
• Pregnant patients with any of the above risk factors
Treatment of vitamin D deficiency
The amount of vitamin D required to treat vitamin D
deficiency depends on a number of factors, including
the baseline 25(OH) vitamin D level, absorptive capacity,
liver capacity for 25-hydroxylation and unknown genetic
factors.
In a patient with normal absorptive capacity, serum 25(OH)D
concentrations increase by approximately 0.7–1.0 ng/ml for
every 100 units (2.5 μg) of added vitamin D, with the larger
increment seen with lower baseline vitamin D levels. For
example, a patient with a 25(OH)D level of 15 ng/ml would
require an additional daily input of about 1 500 IU vitamin D
to reach and sustain a level of 30 ng/ml.
Although there has been some debate about the preferred
form of vitamin D to be used for supplementation, several
studies have shown that both vitamin D2 (ergocalciferol)
and vitamin D3 (cholecalciferol) are effective in maintaining
serum 25(OH)D levels, and are therefore recommended by
the Endocrine Society and NOFSA guidelines.4, 6 Vitamin D
supplementation is mainly administered via the oral route,
and can be taken on an empty stomach or with food, as it
does not require dietary fat for absorption.4 Multiple dosing
regimens have been shown to be effective in the treatment
Page 4
Edition no. 44
Please contact your local Ampath pathologist for more information.
of vitamin D deficiency. Dosing frequency at intervals
up to once monthly seems to be less important than the
cumulative dose.2 Intermittent high dose supplementation
given every three or six months intramuscularly (IMI) has,
however, been shown to increase the risk of falls and
fracture, and is therefore not advised.
The following treatment guidelines, as proposed by
UpToDate2 based on the Endocrine Society Guidelines,4 are
supported by the 2017 NOFSA guidelines:6
• Patients with severe vitamin D deficiency (< 10 ng/ml)
are usually treated with 50 000 IU of vitamin D2/D3 once
weekly for 6 to 8 weeks, or its equivalent of 6 000 IU daily,
followed by maintenance of 800 IU daily thereafter.
• Patients with 25(OH)D levels of 10 to 20 ng/ml may be
given prophylactic vitamin D of 800–1 000 IU daily with a
follow up vitamin D level after three months.
• Individuals with 25(OH)D levels above 20 ng/ml are
maintained on RDA levels appropriate for their age.
• Obese patients, patients with malabsorption syndromes
and those taking medication affecting vitamin D
metabolism require a higher dose of 6 000–10 000 IU
daily to achieve a blood level of 25(OH)D of 20 ng/ml,
followed by maintenance of 3 000–6 000 IU daily.
Follow-up 25(OH)D levels are recommended three to four
months after initiation of therapy.
Patients who do not show an increase in their serum 25(OH)D
level should be worked up for celiac disease or occult
cystic fibrosis, assuming that they were compliant with
treatment.
Some patients with vitamin D deficiency may have co-
existing primary hyperparathyroidism, with calcium being
normal or at the upper limit of the normal range in the
presence of increased PTH. In these individuals, vitamin D
supplementation should be provided to prevent bone loss,
but with caution as hypercalcaemia and hypercalciuria
may rarely develop. Urinary calcium excretion may be
useful for monitoring purposes as it shows a rapid increase
with vitamin D repletion in these patients, and higher values
may identify patients at risk for nephrolithiasis.
In patients with granulomatous disease needing vitamin D
supplementation, vitamin D levels should not be increased
to above 30 ng/ml, as this may be associated with hyper-
calciuria and hypercalcaemia.
Acknowledgements
I would like to thank Dr Stanley Lipschitz, a contributor to the
NOFSA guidelines, for reviewing the draft document and
providing valuable comments.
References
1. Pazirandeh S, Burns DL. Overview of vitamin D. In:
UpToDate, Mulder JE (Ed), UpToDate, Waltham, MA.
(Accessed on May 22, 2017.)
2. Dawson-Hughes B. Vitamin D deficiency in adults:
Definition, clinical manifestations and treatment. In:
UpToDate, Mulder JE (Ed), UpToDate, Waltham, MA.
(Accessed on May 04, 2017.)
3. George JA. Vitamin D status and Cardiometabolic risk
factors in Black African and Indian populations of South
Africa. PhD thesis. University of the Witwatersrand. May
2014: 37, 60, 65.
4. Holick MF, et al. Evaluation, Treatment and prevention
of vitamin D deficiency: an Endocrine Society Clinical
Practice Guideline. J Clin Endocrinol Metab 2011; 96(7):
1911-1930.
5. Institute of Medicine Dietary Reference Intakes for
calcium and vitamin D. Washington DC: Institute of
Medicine; 2010. Available from http//www.iom.edu/
reports/2010/dietary-reference-intakes-for-calcium-and-
vitamin-D.aspx. Refer to chapters on Tolerable upper
intake and Implications and Special Concerns.
6. NOFSA. Revised South African Clinical Guideline for the
diagnosis and management of osteoporosis. 2017: 14, 85,
99, 107, 127.
7. Holick MF. Vitamin D deficiency. NEJM 2007; 357(3): 266-
281.
8. Binkley N, et al. Low vitamin D status despite abundant
sun exposure. J Clin Endocrinol Metab 2007; 92(6): 2130-
2135.
Vitamin D overview: summary, contents and background
This guide helps you understand the scope of Vitamin D overview before or alongside reading the original document. It is based on the catalogue record, credited creator, source, classification and topics shown on this page. It does not replace the original work and does not invent claims about passages that Doxxly cannot verify.
Summary and overview
Vitamin D overview is a 4-page documentcredited to Nadia M. Zephyr. Ampath CHAT edition 44, published in June 2017, reviews vitamin D sources, metabolism, deficiency, screening and treatment. It announces revised reporting thresholds aligned with Institute of Medicine recommendations and the 2017 NOFSA guidelines: deficiency below 12 ng/ml, insufficiency at 12 - 19 ng/ml and sufficiency at 20 ng/ml or above. The document also discusses dietary intake, clinical and biochemical findings, high-risk groups, supplementation, monitoring and safety considerations. It appears in the Medicine & Wellbeing collection, which groups it with other material that readers may use for comparison and further study.
The item can be approached in several ways. A reader looking for a quick orientation can begin with the free five-page preview, inspect the page structure and use the metadata to judge relevance. Someone undertaking deeper research can work through the complete file, search its indexed text, record useful page references and compare its treatment of Vitamin D, Vitamin D deficiency, Laboratory testing, Bone health, Osteoporosis, Supplementation, South Africa, Ampath CHAT with the related resources linked below.
Rather than reducing the work to a single claim, this page treats it as a source that should be read in context. The title, creator, publication source, licence and format all help explain what kind of evidence it may offer. Readers should distinguish the original author's statements from Doxxly's catalogue description, and should cite the original edition when using the material in academic, professional or published work.
Key topics and reader takeaways
The catalogue connects this document with Vitamin D, Vitamin D deficiency, Laboratory testing, Bone health, Osteoporosis, Supplementation, South Africa, Ampath CHAT. These terms offer practical entry points rather than a substitute for close reading. Start by identifying the definitions, examples, arguments, tables or visual explanations attached to each topic. Then note where the creator draws connections, makes distinctions or moves from background material to a conclusion, recommendation, calculation or narrative development.
A useful reading method is to separate description from interpretation. First record what the item actually presents: names, headings, figures, formulas, quotations or stated propositions. Next consider why those details matter within the whole work. Finally compare them with another source from the same subject area. This process helps turn a long digital file into evidence that can be evaluated rather than merely skimmed.
Table of contents and reading guide
The following is an editorial content guide based on the verified catalogue topics. It is not represented as the original author's formal table of contents. Use it to organise notes while moving through the 4 pages in the player.
Part 1
Vitamin D
Use this section of the reading guide to identify how Vitamin D appears in Vitamin D overview, note important terms, and connect the subject to the wider purpose of the work.
Part 2
Vitamin D deficiency
Use this section of the reading guide to identify how Vitamin D deficiency appears in Vitamin D overview, note important terms, and connect the subject to the wider purpose of the work.
Part 3
Laboratory testing
Use this section of the reading guide to identify how Laboratory testing appears in Vitamin D overview, note important terms, and connect the subject to the wider purpose of the work.
Part 4
Bone health
Use this section of the reading guide to identify how Bone health appears in Vitamin D overview, note important terms, and connect the subject to the wider purpose of the work.
Part 5
Osteoporosis
Use this section of the reading guide to identify how Osteoporosis appears in Vitamin D overview, note important terms, and connect the subject to the wider purpose of the work.
Part 6
Supplementation
Use this section of the reading guide to identify how Supplementation appears in Vitamin D overview, note important terms, and connect the subject to the wider purpose of the work.
Part 7
South Africa
Use this section of the reading guide to identify how South Africa appears in Vitamin D overview, note important terms, and connect the subject to the wider purpose of the work.
Part 8
Ampath CHAT
Use this section of the reading guide to identify how Ampath CHAT appears in Vitamin D overview, note important terms, and connect the subject to the wider purpose of the work.
When a heading in the original differs from this guide, follow the original heading in your citation. Page numbers can also vary between editions. Doxxly's direct page field is useful for navigation, but formal references should include the title, creator, source and edition details available in the file itself.
About Nadia M. Zephyr
Doxxly credits Nadia M. Zephyr as the author or creator of Vitamin D overview. This page does not add an unverified biography, job title or institutional affiliation. The attribution is preserved so readers can distinguish the creator from the hosting library and follow the original record when an external author link is available.
Author context matters because a work reflects a particular purpose, audience and point of view. Before relying on the material, consider what the creator set out to explain, when the source was produced and whether later research or revised guidance should also be consulted. For literature and philosophy, compare translations and editions; for technical material, check whether a newer version has superseded the one shown here.
About the source organisation
The recorded source for this item is ampath.co.za. Doxxly provides access and discovery tools but does not claim to be the original publisher unless explicitly stated. Source links, creator attribution and the recorded Publicly available file collected for editorial review licence are displayed to help readers assess provenance and permitted use.
Provenance is especially important for reports, standards, presentations and working spreadsheets. Check the original source for amendments, supporting files and current policy. A trustworthy research workflow keeps the source URL with any notes or downloaded copy, verifies important figures against the original, and avoids treating an archived document as automatically current.
Begin with the title and opening pages, then use the guide above to decide whether to read sequentially or move to a particular topic. The Doxxly player provides previous and next navigation, a direct page field, zoom steps, fit-to-width and fit-to-page modes, rotation and fullscreen. These controls are useful when a page contains small type, a wide table, an image, a scanned layout or a dense sequence of notes.
The first five pages are open to every visitor. A plan unlocks the complete item and full-document search. Search is best used for distinctive names, technical terms or short phrases; broad words can produce too many possible contexts. When you find a useful passage, read the surrounding pages so that a sentence, chart or formula is not separated from its explanation.
If downloading is enabled, members can obtain the original PDF file. Keep the original format when formulas, slide sequencing, pagination or layout carries meaning. Respect the Publicly available file collected for editorial review terms displayed on this page, and use the rights-report link if you believe the attribution or availability needs review.
Research questions to consider
As you read Vitamin D overview, ask which audience the creator addresses, what problem or idea organises the work, what evidence is presented, and which assumptions remain unstated. Note whether important terms are defined consistently and whether examples represent a broader pattern or a narrow case. For quantitative material, record units, time periods, formulas and data sources. For interpretive material, separate the creator's language from your own summary.
A second set of questions concerns relevance today. Which parts remain durable, which depend on their historical or institutional setting, and what would need confirmation from a newer source? Following the tags and the Medicine & Wellbeing collection can reveal useful comparisons. Agreement between sources can strengthen confidence, while disagreement can point to changing definitions, methods, evidence or priorities.
Finally, decide what you need from the item: background knowledge, a quotation, a worked example, a model, a visual explanation or a starting bibliography. That purpose should guide the depth of reading and the notes you keep. Doxxly helps locate and navigate the source; careful interpretation remains the reader's responsibility.